USP <790> Visible Particulates in Injections

USP General Chapter <790>, Visible Particulates in Injections, is a pharmaceutical quality standard that requires all injectable drug products to be essentially free of visible particles. This means every vial, syringe, or ampoule of a sterile injectable product must be inspected and any container showing visible foreign particulate matter must be rejected. The presence of particles in injections is a serious safety concern: if injected into patients, particulate matter can cause harmful effects like blood vessel blockages, inflammation, or allergic reactions. Regulatory agencies worldwide expect manufacturers to prevent and detect visible particulate contamination to protect patient safety

To comply with USP <790>, injection manufacturers conduct a 100% visual inspection of all finished units, under good lighting and background conditions, to weed out any vials or syringes containing visible particles. Trained human inspectors or automated optical inspection machines are used for this step. However, because visual inspection is not perfectly effective (very small particles might escape detection), USP <790> also describes an Acceptable Quality Level (AQL) sampling plan for a second inspection on a subset of units. If the batch passes this statistical AQL test (typically at AQL 0.65% or better), it is deemed “essentially free” of visible particulates. This two-tier approach (100% screening plus AQL sampling) helps ensure that even unseen particles are kept below stringent limits, aligning with the principle of zero tolerance for visible contamination.

Send us a request

Global regulatory agencies have harmonized expectations for visible particulate control. The U.S. FDA mandates that parenteral products be “essentially free from visible particulates” as part of current Good Manufacturing Practice, and emphasizes that meeting USP <790> criteria is necessary but not alone sufficient – manufacturers should implement a holistic particulate control program. In Europe, the European Pharmacopoeia has a similar test (Ph. Eur. 2.9.20) and guidance (Ph. Eur. 5.17.2) which also require visual inspection of injectables and use of AQL sampling to confirm products are practically free of visible particles. The EU’s GMP Annex 1 for sterile manufacturing likewise requires 100% inspection of injectable units for particulate contamination. Japan’s Pharmacopoeia (JP) includes the Foreign Insoluble Matter Test <6.06> for injections, aligning with the same fundamental requirement that no visible foreign particles are present. Across all regions, the message is clear: injectable medicines should not contain any visible debris or contaminants.

Ensuring compliance with USP <790> and equivalent standards involves not only performing rigorous inspections, but also improving manufacturing processes to minimize particle generation. Companies often invest in high-quality lighting, cleanroom environments, and visual inspection training programs for staff. The use of Knapp Kits or visual inspection kits – for example, sets of test vials “spiked” with particles of known sizes – is a best practice to train and qualify inspectors and automated inspection systems. These defect kits help verify that the inspection process can reliably detect particles at the required size threshold (around 100 µm and above). By continuously monitoring and improving particulate control (from sourcing low-shedding materials to filtering solutions and using proper container closure techniques), injectable product manufacturers can meet the stringent expectations of USP <790> and global regulators, thereby ensuring patient safety and regulatory compliance.

Why ChooseNishka Research

Choosing Nishka Research for USP <790> Visible Particulates inspection services means partnering with a team that combines scientific precision with proven regulatory expertise. We understand that visible particulate testing is not just a compliance exercise—it is a matter of patient safety and product integrity. Our facility is equipped with advanced visual inspection technologies, including both manual and automated systems calibrated to detect even the smallest visible contaminants. Every inspection is performed under carefully controlled lighting and background conditions, following USP <790> and global pharmacopoeial standards, ensuring that each batch we evaluate meets the “essentially free from visible particulates” requirement.

What truly sets Nishka Research apart is our commitment to quality assurance and continuous improvement. Our highly trained analysts undergo rigorous qualification using certified particulate reference kits, ensuring consistent accuracy in detection and rejection processes. We also offer comprehensive documentation, data traceability, and customized inspection strategies to meet specific client needs. By choosing Nishka Research, pharmaceutical manufacturers gain a trusted partner dedicated to safeguarding product quality, patient safety, and regulatory compliance—every step of the way.

Looking for a trusted partner to achieve your research goals? schedule a meeting with us, send us a request, or call us at +91 78427 98518 to learn more about our services and how we can support you.

Request a Quote